SeedFolio

HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. The company employs a unique two-site binding mechanism in its targeted therapeutics platform, which enhances the safety and efficacy of treatments while addressing significant unmet medical needs. By concentrating on the root causes of these diseases, HDAX Therapeutics strives to improve patient outcomes and provide long-lasting solutions for various pathologies, including neuropathies and cardiometabolic disorders.

ViAn Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop treatment aimed at replacing traditional invasive injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical testing, ViAn is poised to address significant unmet medical needs within the retinal disease sector, which represents a substantial market opportunity. In addition to its focus on ophthalmology, ViAn is also engaged in creating peptide drugs designed to inhibit angiogenesis, potentially benefiting patients suffering from cancer and other angiogenesis-dependent diseases. Through its innovative approaches, ViAn Therapeutics seeks to enhance patient outcomes and improve the overall quality of life for individuals affected by these conditions.

Vasa Therapeutics is a privately held, preclinical-stage biopharmaceutical company based in Encinitas, California. The company focuses on developing therapies for various vascular diseases, including heart failure, peripheral artery disease, and sarcopenia. Vasa Therapeutics employs a comprehensive platform for drug discovery, allowing for the identification and development of small molecule or peptide therapeutics. This in-house testing funnel enables healthcare professionals to efficiently evaluate potential treatments, aiming to improve outcomes for patients suffering from vascular conditions.

Eversun, headquartered in San Diego, specializes in innovative, portable utility equipment designed to replace traditional fuel-based power and lighting systems. Their flagship product, the eTower, is a versatile, rapidly deployable unit that combines solar power, energy storage, communications, and lighting. Standing up to 23 feet tall in under a minute, the eTower provides reliable power and connectivity for first responders, military units, disaster response teams, event organizers, and construction crews operating in off-grid locations. Setting Eversun apart is its commitment to sustainability; the eTower is primarily solar-powered, backed by lithium batteries, significantly reducing greenhouse gas emissions compared to diesel generators. The company offers customizable solutions, technical support, and digital lighting assessments to meet clients' specific needs, empowering remote site operations with efficient, portable, and eco-friendly technology.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Trio Pharmaceuticals is a San Diego-based company focused on developing innovative cancer therapeutics. Established in 2018, the company specializes in creating dual-action drugs that target immunogenic tumors. These therapeutics are designed to not only halt tumor growth but also selectively counteract immunosuppression within the tumor environment, circumventing traditional immune checkpoint pathways. By targeting specific antigens on both cancer cells and immunosuppressor cells, Trio Pharmaceuticals aims to enhance tumor immunity while improving treatment efficacy, reducing toxicity, and making cancer therapies more affordable for patients. The company is dedicated to addressing high unmet medical needs in cancer treatment through its advanced drug development approach.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactors. Utilizing proprietary technology, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for further reductions at scale. This technology not only enhances production efficiency but also supports ecological sustainability by providing plant-based alternatives to animal-derived materials in the pharmaceutical industry. Tiamat's approach increases the safety and speed of production, positioning it as a strategic partner for scaling operations in burgeoning sectors such as cellular agriculture and gene therapy. The low capital investment required for facility setup makes Tiamat an attractive option in a market poised for substantial growth.

Duo Oncology is a biotechnology company focused on developing innovative nanoparticle technology designed to penetrate established tumors, particularly targeting hard-to-treat cancers such as pancreatic cancer and bile duct cancer. By collaborating closely with leading university scientists and medical oncologists, Duo Oncology aims to redefine treatment outcomes through a novel monotherapy approach that enhances patient care. The company's research is supported by a network of established research organizations, enabling efficient and rapid development of its products. With a commitment to advancing immunotherapy and precision medicine, Duo Oncology seeks to improve recovery times and overall treatment efficacy for patients facing challenging diagnoses.

Anvil Diagnostics is a biotechnology company focused on developing innovative diagnostic solutions. It specializes in creating a sensing technology that can rapidly and accurately detect a wide array of pathogens and genetic markers in blood samples, with the initial aim of identifying hundreds of such targets within a few hours. This technology, based on digital polymerase chain reaction (PCR), is designed to enable precision medicine, particularly for patients with sepsis, by providing timely and precise diagnostic information, thereby helping to resolve clinical ambiguity and improve patient outcomes.

RecoverX develops computational evidence and safe AI technologies to augment medical decision-making and advance new medical evidence.

GroGuru Inc. is a technology company based in La Jolla, California, specializing in smart irrigation solutions for agriculture. Founded in 2014, GroGuru provides software as a service that enables farmers to monitor and manage irrigation effectively. The company leverages an Internet of Things (IoT) sensor network to deliver precise measurements of soil moisture, salinity, and temperature. By utilizing advanced analytics, GroGuru offers real-time insights and recommendations that help farmers optimize water usage, improve crop yields, and make informed decisions regarding irrigation schedules and fertilizer application. The company's solutions aim to promote sustainable farming practices while reducing input costs and conserving vital water resources.

VerImmune, based in Baltimore, Maryland, is an Immuno-Oncology company focused on developing innovative cancer therapies through its proprietary technology known as Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This first-in-class approach aims to harness and redirect pre-existing immune memory from pathogenic infections or childhood vaccines towards tumors. By doing so, VerImmune seeks to offer a transformative treatment option for patients with various types of cancers, especially those facing treatment resistance or limited therapeutic choices. The company's goal is to provide a low-toxicity solution that delivers durable benefits across a broad spectrum of cancer types.

EarthGrid is pioneering a novel approach to tunneling, trenching, and excavation through its patented plasma tunnel-boring technology. This innovative method utilizes high-power plasma torches to vaporize and break down materials such as rock and clay, enabling significantly faster operations and substantial cost savings compared to conventional techniques. The company's network of tunnels aims to enhance infrastructure and connectivity within communities by facilitating the movement of clean renewable energy, extending broadband access to underserved areas, and providing essential services like clean water and efficient transportation for e-commerce. EarthGrid's comprehensive infrastructure solutions are designed to create interconnected and sustainable environments, fostering improved access and quality of life for communities.

Veckta is an innovative energy transition market platform that facilitates the development of distributed energy systems and microgrid projects. By integrating advanced energy system engineering tools with a comprehensive marketplace, Veckta enables businesses and communities to assess their current energy needs and customize solutions tailored to their specific requirements, such as cost, reliability, and emissions. The platform connects clients with vetted capital, construction, and equipment suppliers, ensuring access to the best partners for designing, financing, and building sustainable energy solutions. Through transparent pricing and worldwide support, Veckta empowers users to make informed decisions that contribute to both their operational goals and environmental sustainability.

Ordaos Bio is a biomedical research company based in Manhattan, New York, established in 2019. It focuses on revolutionizing drug discovery and development through the integration of artificial intelligence and biology. The company operates a human-enabled, machine-driven platform that facilitates the design of novel immunotherapies for oncology and chronic inflammatory diseases. By providing an AI-driven drug discovery pipeline, Ordaos Bio empowers researchers to develop treatments that are more effective and safer than conventional methods, thereby addressing significant challenges in medical research and enhancing therapeutic outcomes.

AmplifiDX is a company founded in 2020 and based in Pleasanton, California, specializing in the development of a molecular point-of-care device. This innovative technology offers rapid test results with a focus on ease of use, affordability, and high performance. Designed to deliver clear and actionable COVID-19 results, the device achieves fast turnaround times and high sensitivity comparable to laboratory PCR tests. It is linked to mobile devices, enabling users to receive results in as little as half an hour, thereby facilitating prompt isolation and helping to prevent the spread of the virus.

PreView Medical is a company that specializes in developing an artificial intelligence (AI)-based optical diagnostic tool aimed at improving the detection and diagnosis of prostate cancer. The technology utilizes advanced algorithms to generate a three-dimensional (3D) map of prostate tumors, which assists healthcare professionals in the early detection of prostate cancer and the optimization of treatment for cancer lesions. By focusing on enhancing diagnostic accuracy, PreView Medical aims to contribute to better patient health outcomes in the realm of prostate cancer management.

eGlint is a developer of a miniature biosensing device that identifies multiple biomarkers in blood samples using a small volume of blood. This innovative technology provides the medical industry with an efficient means of deriving data on various biomarkers, which can enhance diagnostic capabilities and improve patient care. By focusing on the analysis of blood, eGlint aims to support healthcare professionals in making informed decisions based on comprehensive biomarker data.

Basilard BioTech is a developer of a nanomechanical gene delivery platform aimed at revolutionizing the cell-based therapies market. The company focuses on leveraging the power and diversity of cell functions to address significant unmet clinical needs, particularly in the realm of Cell and Gene Therapies (CGT). By employing a mechanical approach to gene delivery, Basilard BioTech consistently achieves superior transfection rates, enhanced cell viability, and improved yields compared to traditional biological methods. This innovative technology positions the company to significantly advance therapeutic outcomes for diseases that impact millions of individuals globally.

Amplo Biotechnology is a biopharmaceutical company focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at treating defects related to the neuromuscular junction. These defects can lead to severe health issues, including paralysis and difficulties with breathing and swallowing. The company's lead program, AAV-Dok7, was created by Professor Yuji Yamanashi's research team at the Institute of Medical Science at the University of Tokyo, and it holds promise for addressing various congenital myasthenic syndromes and other rare, severe diseases. Amplo's therapies are administered through intravascular injection, which initiates specific molecular events necessary for effective treatment, thereby enhancing the potential for curative outcomes in affected patients.

Labviva, Inc. is a digital marketplace based in Somerville, Massachusetts, that connects researchers with suppliers of life science products, including reagents, chemicals, and instrumentation. Founded in 2015, the company offers a wide range of laboratory supplies such as antibodies, biological kits, buffers, chromatography materials, and laboratory equipment. Labviva's platform is designed to enhance procurement efficiency by providing real-time inventory tracking, AI-driven purchase automation, and insights into lab purchasing trends. This enables clients to manage their supply chains more effectively, preserve contract pricing with preferred vendors, and establish direct partnerships, all while simplifying content management for suppliers.

Deep Blue Medical Advances, Inc. is a medical device manufacturer specializing in hernia repair solutions. Founded in 2015 and headquartered in Durham, North Carolina, with an additional office in San Francisco, the company develops innovative surgical devices, including its T-Line® hernia mesh and anchor clips. These products are designed to address the high rates of hernia occurrence and recurrence, which pose significant clinical challenges and costs. The T-Line mesh features integral suture-like extensions to enhance fixation strength at the tissue interface, thereby reducing the risk of mesh failure. Additionally, the Anchor Clip fixation device facilitates quicker and more efficient implantation of the mesh. By improving surgical outcomes and patient experiences, Deep Blue Medical Advances aims to make a substantial impact within the $1.1 billion global hernia device market.

Inspirit is an education technology company based in Palo Alto, California, that specializes in virtual reality tools for science and STEM education. Founded in 2019, the company provides a next-generation learning platform that includes a comprehensive library of immersive virtual labs and simulations accessible on various desktop, laptop, and VR platforms. Inspirit's software enables educators to create custom simulations and experiments using no-code creator tools, facilitating the integration of assessments and quizzes tailored to specific learning objectives. The platform is designed to enhance classroom management and supports group or networked lab sessions, fostering deep engagement and critical reasoning among students through active participation in virtual environments. By transforming traditional science courses, Inspirit aims to elevate the educational experience and improve knowledge retention in learners worldwide.

Allotrope Medical Inc. is a Houston-based medical device company that specializes in manufacturing surgical devices aimed at enhancing surgical procedures. The company's flagship product, StimSite, is an intuitive handheld device designed specifically to assist surgeons in quickly and accurately identifying ureters during operations. This device not only aids in ureter localization but also functions as a blunt dissection tool, streamlining the surgical process. By employing a simple single-button design, Allotrope Medical's device eliminates the need for additional pre and post-operative procedures, thereby improving efficiency in pelvic surgeries. Established in 2016, the company focuses on innovative solutions that enhance surgical accuracy and patient safety.

Maxwell Biomedical, Inc. is a medical device company focused on developing innovative solutions for the treatment of atrial fibrillation. Established in 2018 and located in Solana Beach, California, the company is pioneering a device designed to provide real-time, pain-free left atrial pacing to restore normal sinus rhythm in patients experiencing atrial fibrillation. This device continuously monitors for episodes of atrial fibrillation and employs a unique therapy called Spatial Resynchronization Therapy (SRT) to terminate these episodes without shock, thereby reducing the overall burden of the condition. Maxwell Biomedical's technology incorporates a fully integrated atrial fibrillation care system that facilitates remote patient management and telehealth capabilities, allowing healthcare providers to monitor and manage patients more effectively while potentially slowing or halting disease progression.

Ivy is a turn-key service powered by intelligent software providing equitable solar access to residents and predictable returns to owners.

PercAssist specializes in the development of percutaneous balloon catheters aimed at enhancing left ventricular function and facilitating myocardial recovery. The company's innovative design features a battery-powered, non-blood contact extra-vascular system that simplifies procedural implementation. By improving treatment options for severe heart failure, PercAssist seeks to address significant unmet needs within the medical community. The technology is designed to reduce recovery time, lower the risks of long-term complications and hospitalizations, and ultimately improve patient survival rates and quality of life. With a dedicated founding team and clinical advisory board, PercAssist is committed to advancing cardiac care.

Tiamat Sciences is a start-up focused on producing affordable, animal-free growth factors and biomolecules through innovative plant-based bioreactors. Utilizing proprietary technology, the company manufactures a diverse array of high-value proteins, including antigens and growth factors, achieving significant cost reductions—up to 10 times lower than traditional methods, with potential for further reductions at scale. This technology not only enhances production efficiency but also supports ecological sustainability by providing plant-based alternatives to animal-derived materials in the pharmaceutical industry. Tiamat's approach increases the safety and speed of production, positioning it as a strategic partner for scaling operations in burgeoning sectors such as cellular agriculture and gene therapy. The low capital investment required for facility setup makes Tiamat an attractive option in a market poised for substantial growth.

Strategikon Pharma, Inc. is a technology company based in San Rafael, California, founded in 2016. It specializes in developing software solutions that streamline the outsourcing processes between sponsors and providers in the pharmaceutical industry. Its flagship product, Clinical Maestro, is a comprehensive software platform designed for the end-to-end management of clinical business operations, including planning, outsourcing, and budgeting for clinical trials. This innovative software replaces traditional, labor-intensive methods, often reliant on Excel, which are costly and inefficient. Clinical Maestro integrates workflows to enhance communication and data sharing between biopharmaceutical companies and their outsourcing partners. The platform facilitates clinical financial management, vendor performance metrics, and contract lifecycle management, while also offering consulting services for new clinical business operations. Case studies with leading pharmaceutical companies have shown that Clinical Maestro can lead to significant savings and improved accuracy in budgeting, demonstrating its effectiveness in transforming clinical trial management.

Abintus Bio, Inc. is a preclinical stage gene therapy company founded in 2020 and headquartered in Encinitas, California. The company specializes in in vivo immune cell reprogramming, developing innovative products that modulate immune cells within their native environment. By leveraging proprietary vectors and related technologies, Abintus Bio aims to enhance patient outcomes and access through its portfolio of first-in-class product candidates. These therapies are designed to directly empower patients' immune cells, enabling them to better combat diseases from within their own bodies.

Ready, Set, Food! is a California-based company founded in 2017 that specializes in manufacturing and selling food products designed for infants. The company's main goal is to help parents reduce the risk of their babies developing allergies to common foods such as peanuts, eggs, and milk. Ready, Set, Food! offers a gentle, daily system that simplifies the introduction of these allergenic foods into infants' diets, potentially lowering the risk of allergies by up to 80%. The products are available for purchase online, making them accessible to a wide range of consumers.

Optimize Health is a provider of a digital healthcare platform focused on enabling Remote Patient Monitoring (RPM) programs. The company offers user-friendly equipment and software designed to support healthcare providers in managing patient care efficiently. Its platform automatically tracks medication doses and sends reminders to patients, ensuring adherence to treatment plans by syncing with smartphones or tablets. This system not only enhances patient engagement but also assists providers in complying with billing requirements for new Medicare codes, promoting profitability for physicians from the outset. Through its innovative approach, Optimize Health aims to improve health outcomes and streamline the management of chronic conditions.

Everest Labs, founded in 2018 and based in Fremont, California, specializes in developing advanced robotics solutions for the waste management and scrap metal industries. The company's flagship product, Celer, employs artificial intelligence, machine learning, and computer vision to enhance the sorting and quality control processes at material recovery facilities. By integrating these technologies, Everest Labs aims to increase the quality of recyclables while minimizing reliance on human labor, thereby supporting revenue growth for waste management companies. The company is focused on fostering sustainability in the industry by encouraging the use of recycled materials in manufacturing and packaging. Ultimately, Everest Labs aspires to establish itself as a leading provider of AI and robotics solutions in complex environments like waste management.

Buzz Solutions, Inc. is a technology company based in Palo Alto, California, founded in 2017. It specializes in developing an artificial intelligence-based software platform designed for energy infrastructure applications, particularly in the inspection and maintenance of power lines. The company’s platform utilizes image-recognition technology to identify defects in utility infrastructure and automates the analysis of visual data captured by drones, helicopters, and field personnel. By providing actionable insights and predictive analytics, Buzz Solutions enables power utilities to efficiently detect faults and anomalies, resulting in significant cost and time savings. The platform streamlines the process of data organization and analysis, facilitating condition-based maintenance and enhancing safety while also contributing to the prevention of wildfires and power outages linked to infrastructure failures.

Chronus Health, Inc. is a medical technology company that specializes in developing a portable diagnostic device capable of delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and headquartered in Mountain View, California, the company utilizes advanced microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time diagnostic capabilities. This innovative system allows for the delivery of lab results within minutes, significantly enhancing the speed of diagnosis and improving patient outcomes by enabling timely and informed treatment decisions.

Tourmo is a technology company founded in 2014 and based in San Diego, California, that specializes in developing advanced software solutions for telematics data collection via smartphones. With a focus on automating manual processes, Tourmo utilizes artificial intelligence to simplify the complexities associated with transportation workforces, vehicles, and network fleets. The company's platform delivers contextualized business intelligence and real-time decision-making capabilities, enabling organizations to enhance their operational efficiency and support their critical networks of personnel, vehicles, customers, and partners. Tourmo holds two U.S. patents related to telematics and drive-data collection, positioning itself as a leader in providing innovative solutions for mobile phone manufacturers, carriers, and app development companies in the U.S. and Europe.

AccessParks is a provider of outdoor internet services that delivers broadband connectivity to parks and campgrounds. The company specializes in fully managed fiber optic-fed broadband access, enabling over 4,000 devices to stream video simultaneously without interruption. AccessParks oversees the entire network, from the fiber infrastructure to the devices utilized by guests, ensuring reliable performance. With a dedicated 24/7 support and network operations center, AccessParks continuously monitors and optimizes network operations, allowing park authorities to offer consistent and high-quality internet access to their visitors. In addition to broadband services, AccessParks also provides value-added IoT software applications, enhancing the overall experience for users in outdoor settings.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Resynergi is a company dedicated to addressing the global challenge of waste plastics by developing innovative biorefining technology. It specializes in manufacturing modular, low-emission systems that convert traditionally non-recyclable plastics into environmentally friendly fuels and chemical products. Utilizing a microwave-based technology, Resynergi's systems efficiently transform unrecycled waste plastics into biodiesel and other low carbon-intensity fuels. These systems are designed to be easy to deploy, scalable, and highly cost-effective, making them an attractive solution for clients seeking sustainable alternatives in fuel production. Through its efforts, Resynergi aims to promote a circular economy and reduce the environmental impact of plastic waste.

Regenosine is a healthcare company that develops regenerative therapies for tissue regeneration, with a focus on cartilage repair and joint preservation. Its therapies leverage a purinergic system to regulate tissue homeostasis and restore adenosine levels, enabling the healing potential of adenosine to support tissue regeneration.